SPAC DYNS shareholders approve merger with biotech Senti Biosciences
Evgeny Gromov/iStock via Getty Images

Shareholders of SPAC Dynamics Special Purpose Corp. (DYNS) have approved a proposed merger with cellular therapy developer Senti Biosciences. 
In a filing, DYNS said that shareholders voted in favor of the deal, which pegs the combined company with a pro form equity value of $601M. The companies announced the merger deal in December.
Senti Bio has been working on chimeric antigen receptor natural killer, or CAR-NK, cellular therapies for the treatment of various cancers. Its lead products are SENTI-202 for the treatment of acute myeloid leukemia, or AML, and SENTI-301 for the treatment of liver cancer. Senti hopes to apply with the FDA to begin clinical testing in 2023.
The biotech company also has collaborations with Rocheâs Spark Therapeutics and Bayerâs Bluerock Therapeutics for the development of gene therapies that utilize Sentiâs Gene Circuit bioengineering technology.
DYNS, which counts Cathie Woodâs ARK Investment Management as a backer and Illuminaâs (ILMN) former chief technology officer as its chief executive, raised $200M through an initial public offering in May 2021.